
Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
By Blake Brittain (Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the …